YK012
As of the edition of 20 October 2026, YK012 is a drug known only by a code name: in active development; acts on CD19.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Code name only
- Registered trials
- 6, 0 stopped early
- Disease areas
- Immune system; Blood and lymph; Cancer; Skin and connective tissue; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD19 | B-lymphocyte antigen CD19 | P15391 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 0 | 4 | 0 |
| Phase 2 | 2 | 0 | 2 | 0 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Excyte Biopharma | Lead sponsor of trials | 2023 to now |